<DOC>
	<DOCNO>NCT01566656</DOCNO>
	<brief_summary>Recent advance allogeneic hematopoietic cell transplantation ( allo-SCT ) lead reduce intensity preparative regimens non-myeloablative reduce toxicity associate transplant . Consequently non-relapse mortality reduce , include elderly patient comorbidities . However , despite benefit term toxicity , excessive reduction intensity preparative regimen may favor relapse initial illness . Thus , acute chronic graft-versus-host disease opportunistic fungal viral infection always serious complication . The aim study check new modality reduce intensity preparative regimen combine total lymphoid irradiation ( TLI ) thymoglobulin ( ATG ) , would limit toxicity treatment reduce incidence acute GVHD allogeneic transplantation preserve antitumor benefit .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Using Non-myeloablative Preparative Regimen Total Lymphoid Irradiation Anti-thymocyte Globulin Older Patients With Relapsed Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Any patient one follow hematolymphoid malignancy syndromes allogeneic stem cell transplantation warrant . Specific disease category include : nonfollicular indolent advance stage NonHodgkin Lymphomas , Mantle Cell Lymphoma , Marginal zone lymphoma , MALT , T cell lymphoma , Chronic Lymphocytic prolymphocytic Leukemia , Hodgkin Disease , Waldenström macroglobulinemia . Tcell NOS , angioimmunoblastic lymphoma , HTLV1 , Tgamma/delta , anaplastic lymphoma Sezeay syndromes include careful assessment PI protocol steer committee . Patients must least partial remission ( accord standard criterion ) salvage therapy ( ~one month ) start condition regimen . Patient age &gt; 50 less 66 year , patient &lt; 50 year age preexist medical condition prior therapy consider high risk regimenrelated toxicity associate conventional myeloablative transplant . A fully HLAidentical sibling match unrelated donor available ( 10/10 HLA match ) . Patients one antigen mismatch donor consider discussion transplant team Principal Investigator . Patient must competent give consent . Patients progressive hematolymphoid malignancy despite conventional therapy , partial remission month precede transplantation . Patients DLBCL cutaneous T cell lymphoma Uncontrolled CNS involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Organ dysfunction define follow : Cardiac function : ejection fraction &lt; 30 % uncontrolled cardiac failure Pulmonary : DLCO &lt; 40 % predict Renal : Serum creatinine &gt; 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m² Liver function abnormality : elevation bilirubin &gt; 3 mg/dl and/or transaminases &gt; 4x upper limit normal Karnofsky performance score &lt; 70 % Patients poorly control hypertension multiple antihypertensive Documented fungal disease progressive despite treatment Viral infection : HIV positive patient . Hepatitis B C positive patient evaluate case case basis Psychiatric disorder psychosocial problem opinion primary physician Principal Investigator would place patient unacceptable risk regimen . Patients prior malignancy diagnose &gt; 5 year ago without evidence disease eligible . Patients prior malignancy treat &lt; 5 year ago life expectancy &gt; 5 year malignancy eligible .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>Non-myeloablative preparative regimen</keyword>
	<keyword>Total lymphoid irradiation</keyword>
	<keyword>Anti-thymocyte globulin</keyword>
	<keyword>Lymphoid malignancy</keyword>
</DOC>